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Background: This work aimed to synthesize a cathepsin B (CTSB)-cleavable tumor-targeting prodrug peptide
doxorubicin (PDOX) and study the in vivo efficacy and toxicities on an animal model of gastric peritoneal
carcinomatosis (PC).
Methods: PDOX was synthesized using doxorubicin (DOX) attaching to a CTSB-cleavable dipeptide Ac-Phe-Lys and
a para-amino-benzyloxycarbonyl (PABC) spacer. PC model was established by injecting VX2 tumor cells into the
gastric sub-mucosa of 40 rabbits, which then were randomized into 4 groups: the Control (n = 10) without
treatment, the HIPEC (n = 10) receiving cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy
(HIPEC), the PDOX (n = 10) and the DOX (n = 10) receiving systemic chemotherapy with PDOX 50.0 mg/kg or
DOX 5.0 mg/kg, respectively, after CRS + HIPEC.
Results: The median overall survivals (OS) were 23.0 d (95% CI: 19.9 d - 26.1 d) in the Control, 41.0 d (36.9 d - 45.1 d) in
the HIPEC, 65.0 d (44.1 d - 71.9 d) in the PDOX, and 58.0 d (39.6 d - 54.4 d) in the DOX. Compared with the Control,
the OS was extended by 70% in the HIPEC (p < 0.001) and further extended by 40% in the DOX (p = 0.029) and by
58% in the PDOX (p = 0.021), and the PC severity was decreased in the HIPEC and further decreased in the PDOX
and DOX. Animals receiving DOX treatment showed hematological toxicities with marked reduction of white
blood cells and platelets, as well as cardiac toxicities with significant increases in creatine kinase mb isoenzyme,
evident myocardium coagulation necrosis, significant nuclear degeneration, peri-nucleus mitochondria deletion,
mitochondria-pyknosis, and abnormal intercalated discs. But these toxicities were not evident in the PDOX.
Conclusions: PDOX is a newly synthesized tumor-targeting prodrug of DOX. Compared with DOX, PDOX has
similar efficacy but reduced hematological and cardiac toxicities in treating rabbit model of gastric PC.
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GC is one of the most common malignancies in devel-
oping countries, where it ranks second in terms of inci-
dence rate and third in terms of mortality rate among
the male population, and ranks fourth in terms of both
incidence rate and mortality rate among the female
population, according to the most recent global statistics
[1,2]. GC is also the third leading cause of cancer mor-
tality in China [3], where over 70% of GC has already
become clinically advanced by the time of surgical ex-
ploration, thus surgical resection alone is no longer
curative [4].
PC in GC has long been considered as a fatal clinical
entity. It is defined as the implantation of tumor cells
throughout the peritoneal cavity and characterized by
the presence of tumor nodules of various size, number,
and distribution on the peritoneal surface as well as ma-
lignant ascites, frequently resulting in locoregional mor-
bidity without broader systemic metastases. Patients
with gastric PC face a dismal outcome, with a median
survival of about 6 months [5].
There is no standard treatment for gastric PC. Current
treatments for such PC are systemic chemotherapy, best
support care and palliative therapy. In order to tackle
this problem, a new treatment modality called CRS plus
HIPEC has been developed over the past 3 decades, taking
advantages of surgery to reduce visible tumor burden, and
regional hyperthermic chemotherapy to eradicate micro-
metastases [6]. Increasing evidence has suggested that the
combination of CRS and HIPEC could bring survival
benefit for selected patients with gastric PC. In our pre-
vious experimental study [5], we have also proved that
CRS +HIPEC could indeed bring survival benefit with ac-
ceptable safety, providing evidence to support this com-
bined strategy to treat selected patients with gastric PC.
During the development of PC, GC cells secrete en-
zymes to facilitate cancer cells seeding and colonization
on the peritoneum. CTSB is one of the key enzymes in
this critical process, over-expressed in GC as well as
other cancers [7-9] and actively involved in cancer inva-
sion [10-12]. On the other hand, it is extremely low
expressed in normal cells and inactive or loses activity as
soon as it is dispersed in aqueous media away from cells
[13]. Thus CTSB has long been considered as a candi-
date target in cancer therapy [14].
It has been established in the MAGIC trial that the
anthracycline-contained regimen is a useful chemother-
apy for GC [15]. DOX is a typical representative of
anthracyclines. Although DOX is an important drug in
chemotherapy, its toxicities are evident, such as cardiac tox-
icities and bone marrow suppression. To retain the thera-
peutic effect while reducing the side effects, Dubowchik
et al [16-18] designed a smart prodrug of DOX, PDOX
(Figure 1). In this modified DOX, Ac-Phe-Lys is adipeptide specific for CTSB, and PABC (para-aminoben-
zyloxycarbonyl) is a self-immolative spacer [16]. The pro-
drug is inactive when there is little CTSB activity, such as
normal tissues and peripheral blood, thus avoiding the
side effects on normal tissue. During cancer invasion, acti-
vated CTSB is over expressed on the exterior membrane
of the invading cancer cells [19,20], which cleaves the
Ac-Phe-Lys dipeptide at the Lys-PABC bond [16]. Then
the exposed PABC spacer can self-hydrolyze upon deacy-
lation [21] and free DOX molecules are released, resulting
in direct killing of the invading cancer cells [16].
In this study, we synthesized the PDOX and evaluated
the efficacy and safety of CRS +HIPEC with molecular
targeted therapeutic regimen PDOX for targeted treat-
ment of rabbit model of gastric PC.
Results
Synthesis and identification of PDOX
PDOX was successfully synthesized according to the previ-
ously reported 7-step chemical process (Figure 1) [16-18].
PDOX (Ac-Phe-Lys-PABC-Dox · HCl) was a red solid
powder with molecular weight of 1046.51 (MS: m/z calcu-
lated for C52H60ClN5O16: 1046.52, found: 1046.50), chemical
purity of 99.1% (by HPLC), structure of C52H60ClN5O16
(by both of H1-NMR and C13-NMR) (Figure 2) and
melting point of 180°C (decomposition), which is stable
at -5°C to 0°C for 36-54 months, ambient temperature
for 24 months, solvable in water, partially solvable in
methanol and ethanol. PDOX used in this study was
stored in the dark, dry area at 4°C.
PC model construction and histopathological
characteristics
Rabbit model of gastric PC was established in all animals
(100%, 40/40). On d 8 after tumor cells inoculation,
small, hard and transparent tumor nodules developed on
the greater omentum, and typical ulcerative cancer
about 0.5-1.0 cm in diameter formed on the antrum of
the stomach. No ascites was observed. No obvious PC
was found in other regions. There were no differences in
the PC severity among all the rabbits. This could be
equivalent to clinical stage I PC by Gilly criteria [22]
(Figure 3A).
All investigated tumor specimens showed extensive inva-
sive growth and tissue destruction. The tumors, on the
greater curvature of the gastric antrum, penetrated the mu-
cosal layer to form ulcers. Histopathological study showed
tumor nests penetrating the entire stomach wall, with typ-
ical invasion into the muscle layer and the gastric glands
(Figure 3B). The tumor cells are round, oval or atypical
morphology with many pathological mitotic figures. There
were also conspicuous infiltration of lymphocytes, plasma
cells and other inflammatory cells (Figure 3C). Apoptotic
and necrotic tumor cells were observed in the central
Figure 1 (See legend on next page.)
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Figure 1 PDOX structure (shown in the box), chemical synthesis and action mechanism. PDOX was successfully synthesized according to
the 7-step chemical process. Its chemical structure is Ac-Phe-Lys-PABC-Dox·HCl (shown in the box), and the molecular formula is C52H60ClN5O16.
PDOX contains a CTSB-cleavable dipeptide Ac-Phe-Lys (double red slashes) a PABC spacer (red slash) and anti-cancer drug DOX. When PDOX
reaches CTSB-enriched area such as the invasion front of cancer, the Ac-Phe-Lys dipeptide is cleaved by CTSB at the Lys-PABC bond, exposing the
PABC spacer that is then hydrolyzed spontaneously (red slash), releasing free DOX at the cancer invasion front. Thus PDOX could exert cytotoxicity to
invading cancer cells while protecting normal cells from excessive drug exposure, a strategy called passive targeted therapy. CTSB: cathepsin B.
Tang et al. Molecular Cancer 2014, 13:44 Page 4 of 17
http://www.molecular-cancer.com/content/13/1/44region of the tumor nodules (Figure 3D). Typical PC pre-
sented as tumor nodules on the surface of the omentum
(Figure 3E) and intraperitoneal lymph node metastases
were also observed (Figure 3F).
Typical ulcerative cancer with PC was observed in
post mortem pathological examinations of rabbits in the
Control. The stomach wall was totally invaded by the
tumor to create cancer ulcer encased by confluent nod-
ules on the greater omentum, forming a big tumor
block. The abdominal wall and diaphragm were totally
invaded by the tumor. Many tumor nodules formed on
the intestinal wall, the mesentery and the retroperito-
neum. Bloody ascites could be more than 100 mL. All
the features are similar to the clinicopathologic charac-
teristics of gastric PC in patients (Figure 3G).
Survival
Animal was observed to record OS. Two long surviving
rabbits (one in the PDOX and another in the DOX, liv-
ing more than 100 d) were euthanized on the 100th day
by an overdose injection of 2% pentobarbital sodium.
The median (95% confidence interval, CI) OS was 23.0 d
(19.9 - 26.1 d) in the Control, 41.0 d (36.9 - 45.1 d) in
the HIPEC, 65.0 d (44.1 - 71.9 d) in the PDOX and 58.0
d (39.6-54.4 d) in the DOX. Compared with the Con-
trol, the OS was extended by at least 70% in the HIPEC
(p < 0.001, log rank test). Compared with the HIPEC, the
OS was further extended by 40% in the DOX (p = 0.029,
log rank test) and by 58% in the PDOX (p = 0.021, log
rank test) (Figure 4A).
Tumor burden at the survival endpoint
At the study endpoint, the tumor burden in the Con-
trol was heaviest, with tumor weight of (137.51 ±
16.09) g, tumor-bearing ratio (tumor weight to body
weight) of (7.88 ± 0.85)%, bloody ascites of (65.50 ±
33.45) mL, and ePCI score of (9.50 ± 2.17). Compared
with the Control, the HIPEC had significantly reduced
tumor weight (76.50 ± 11.41) g (p = 0.007) and tumor-
bearing ratio (3.94 ± 0.54)% (p = 0.001), but not ePCI
score (9.50 ± 2.17)% (p = 0.420) and bloody ascites
[(29.16 ± 15.30) mL, p = 0.085]. Compared with the HIPEC,
PC severity was further decreased in both the PDOX and
the DOX, with ePCI score (6.40 ± 2.07, p = 0.020 in both
PDOX and DOX vs. HIPEC) and bloody ascites (0.00 mL,
p < 0.001 in PDOX and DOX vs. HIPEC); while therewere no significant differences in tumor weight [(65.30 ±
14.55) g, p = 0.552, PDOX vs. HIPEC; (48.74 ± 16.31) g,
p = 0.180, DOX vs. HIPEC)] and tumor-bearing ratio
[(2.91 ± 0.69)%, p = 0.552, PDOX vs. HIPEC; (2.13 ± 0.78)%,
p = 0.180, DOX vs. HIPEC]. There were no significant dif-
ferences in tumor burden between the PDOX and the
DOX (Table 1).
Body weight changes
The body weight of each animal was recorded every 4 d.
No significant differences were found in initial body
weight of 4 groups before the treatment. Perioperative
body weight decreased in all groups because of the over-
night fasting. In the Control, the body weight recovered
once food intake was resumed but again decreased pro-
gressively till the study endpoint. In the 3 treatment
groups, postoperative body weight decreased consider-
ably after model construction and to the lowest 4 d after
CRS +HIPEC, and then stayed at a low level during the
post-operative phase until chemotherapy had been com-
pleted. The body weight began to increase at d 44 in the
HIPEC and d 56 in both the PDOX and the DOX, and
gradually increased to a higher level, which was related
to both tumor growth of the living tumor-bearing rab-
bits and death of the failure rabbits with lesser body
weight. Thereafter, body weight decreased progressively
again until the study endpoint in both the PDOX and
the DOX (Figure 4B).
Postmortem pathological examinations
By the time of animal death, detailed information on post-
mortem pathological examinations was listed in Table 2.
In addition to systematic examinations of all ana-
tomic sites for possible cancer metastases, particular at-
tention was paid to lung and liver metastases. As
shown in Figure 5, in the Control, extensive liver me-
tastases were observed in 8 animals, but no pulmonary
metastases were evident in all animals, because of the
very aggressive growth behaviors of the tumor led to
short OS in this group of animals (Figure 5 A2, B2). In
the HIPEC, as animals lived much longer because of
CRS + HIPEC, fewer liver metastases were observed in
4 animals, but considerably much more pulmonary me-
tastases were observed in 7 animals (Figure 5 A3, B3).
In the PDOX and DOX, animals developed much fewer
metastases in both the livers and the lungs, although
Figure 2 Structure identifications confirmed by H1-NMR (A) and C13-NMR (B).
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Figure 3 The characteristics of rabbit model of gastric PC and the HE stained micrographs. (A) The picture of early rabbit model of gastric
PC where conspicuous tumor nodules scattered on the peritoneum and the greater curvature of the stomach; (B) the pictures of ulcerative GC;
(C&D) HE stained picture under microscope showing the invasive growth of tumor cell nests infiltrating the gastric wall (panel C, 400×) and necrotic
tumor cells in the area of insufficient blood supply (panel D, 400×); (E) tumor nodules on the surface of the omentum (200×); (F) intraperitoneal
lymph node metastases (200×); (G) post mortem pathological examinations of a rabbit.
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animals received not only CRS + HIPEC to control local
regional metastases but also systemic chemotherapy to
control hematogenous metastases and lymphatic metas-
tases (Figure 5 A4, B4, A5, B5).
Peripheral blood profile and major biochemistry changes
There were no differences in peripheral blood cell
counts on d 2, d 6 and d 14 among the 4 groups, but the
white blood cells and platelets were significantly de-
creased on d 36 after systemic chemotherapy in the
DOX (p < 0.05). There were no differences in the hepatic
and renal functions throughout the experiment among
the 4 groups. In terms of cardiac functions parameters,
there were no differences in creatine kinase and creatinekinase mb isoenzyme on d 2, d 6 and d 14 among the 4
groups, but creatine kinase mb isoenzyme was signifi-
cantly increased on d 36 after systemic chemotherapy in
the DOX (p < 0.05). Of particular attention, 2 animals in
the DOX with short OS of 47 d and 53 d had exception-
ally higher serum creatine kinase mb isoenzyme levels,
467.5 U/L and 656.4 U/L, respectively (p < 0.05) (Table 3).
Detailed studies on myocardium toxicities
Histopathological studies under both light microscope
and transmission electron microscope found no myocar-
dium toxicities in the Control, the HIPEC and the
PDOX, but significant histopathological changes of myo-
cardium were found in all animals (100%, 10/10) in the
DOX, including coagulation necrosis of the myocardium
Figure 4 In vivo effects of PDOX on rabbit PC model. (A) Kaplan-
Meier survival curves for the Control, HIPEC, PDOX and DOX; (B) Body
weight changes in those groups.
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(Figure 6 C1, H1, P1, D1 black arrows). Electron trans-
mission micrographs showed that normal myocardium
with abundant mitochondria packed around normal nu-
cleus in the Control and HIPEC, rich normal but with
slightly dilated cristae mitochondria scattered around
normal nucleus in the PDOX, nearly absent mitochon-
dria around the morphologically senile and degenerativeTable 1 The ePCI score at survival endpoint in 4 groups of ra
Control (n = 10) HIPEC
The ePCI score in different regions
Region I 0 ~ 3 (3) 0 ~
Region II 3 ~ 3 (3) 3 ~
Region III 1 ~ 3 (3) 0 ~
Region IV 0 ~ 3 (3) 0 ~
Ascites (mL)* 12.0 ~ 113.4 (56.0) 0.0 ~ 9
The ePCI score§ 7 ~ 13 (11) 5 ~
*Ascites: p = 0.323, HIPEC vs. Control; p < 0.001, PDOX vs. HIPEC; p < 0.001, DOX vs. H
§The ePCI score: p = 0.073, HIPEC vs. Control; p = 0.020, PDOX vs. HIPEC; p = 0.020, Dnucleus in the DOX. In addition, partial myocardium-
lytic necrosis (yellow arrow) and mitochondria-pyknosis
away from the nucleus (red arrow) were also evident in
the DOX. Complete, clear and continuous lines of nor-
mal intercalated discs in the Control, the HIPEC and the
PDOX, but obscure, loosing and discontinuous interca-
lated discs were found in the DOX (white arrows).
Discussion
There is no standard treatment for gastric PC. CRS plus
HIPEC represent a multidisciplinary approach to this
problem. It was first reported in 1988 by Fujimoto et al
[23] on 15 patients with PC secondary to advanced GC,
with a mean survival of 7.2 ± 4.6 months with acceptable
morbidity. This new treatment modality gradually gains
acceptance in many countries. The reported studies use
different PCI scoring system to evaluate the extent of
PC and different HIPEC approaches, but they produce
similar results that CRS +HIPEC provides treatment
benefit. In order to more objectively evaluate such treat-
ment, it is necessary to study this treatment modality
under experimental conditions, in which most of the
confounding factors could be well controlled.
In our previous study [24,25], we have established a
stable rabbit model of gastric PC by injecting VX2 can-
cer cells into the sub-mucosal layer of the stomach. The
non-immuocompromised larger animal model is charac-
terized by typical ulcerative GC with progressive PC,
making it more suitable for surgical interventional stud-
ies to evaluate CRS and HIPEC against gastric PC. This
rabbit model of gastric PC has provided us with suitable
platform to evaluate different therapeutic approaches
against PC. On this first large animal model of gastric
PC, we proved that CRS + HIPEC with docetaxel and
carboplatin could significantly prolong the OS by at least
60% (40 d vs. 23 d) with acceptable safety. The addition
of molecular targeted therapy with PDOX could provide
much better survival benefits with satisfactory drug
safety.
This study provided new approach of CRS + HIPEC
combined with molecular targeted therapeutic regimenbbits [range (median)]
(n = 10) PDOX (n = 10) DOX (n = 10)
3 (2) 0 ~ 3 (0) 0 ~ 3 (0)
3 (3) 3 ~ 3 (3) 3 ~ 3 (3)
3 (3) 0 ~ 3 (1) 0 ~ 3 (1)
3 (1) 0 ~ 3 (0) 0 ~ 3 (0)
4.0 (18.1) 0.0 ~ 0.0 (0.0) 0.0 ~ 0.0 (0.0)
12 (9) 3 ~ 9 (6) 3 ~ 9 (6)
IPEC.
OX vs. HIPEC; p = 0.474, PDOX vs. DOX.
Table 2 Results of post mortem pathological study in 4 groups, expressed as % of rabbits
Control (n = 10) HIPEC (n = 10) PDOX (n = 10) DOX (n = 10) p1 p2 p3 p4
Ulcerative GC 100.0 100.0 100.0 100.0 NS NS NS NS
Incision metastases 100.0 30.0 30.0 20.0 0.001 NS NS NS
Pulmonary metastases 0.0 70.0 30.0 30.0 0.001 NS NS NS
Chest wall metastases 0.0 20.0 10.0 0.0 NS NS NS NS
Pleural effusion 10.0 70.0 30.0 30.0 0.008 NS NS NS
Virchow lymph nodes metastases 30.0 70.0 60.0 40.0 NS NS NS NS
Pericardium metastases 0.0 20.0 0.0 0.0 NS NS NS NS
Cancerous diaphragm 100.0 70.0 20.0 20.0 NS 0.028 0.028 NS
Greater omentum cake 100.0 80.0 40.0 50.0 NS NS NS NS
Liver metastases 80.0 40.0 30.0 30.0 NS NS NS NS
Spleen metastases 0.0 0.0 20.0 0.0 NS NS NS NS
Retroperitoneum metastases 100.0 60.0 60.0 50.0 0.029 NS NS NS
Left renal metastases 0.0 10.0 0.0 0.0 NS NS NS NS
Right renal metastases 0.0 0.0 0.0 0.0 NS NS NS NS
Kidney capsule invasion 100.0 50.0 0.0 20.0 0.012 0.012 NS NS
Intestine wall seeding 100.0 80.0 20.0 10.0 NS 0.009 0.002 NS
Mesentery seeding 100.0 80.0 30.0 10.0 NS 0.028 0.002 NS
Abdominal wall cancer 100.0 60.0 30.0 0.0 0.029 NS 0.004 NS
Pelvic seeding 100.0 50.0 30.0 10.0 0.170 NS NS NS
Bladder rupture 0.0 0.0 20.0 10.0 NS NS NS NS
Urine retention 50.0 50.0 30.0 10.0 NS NS NS NS
By 2-sided chi-square (χ2) test. p1, HIPEC vs. Control; p2, PDOX vs. HIPEC; p3, DOX vs. HIPEC; p4, PDOX vs. DOX.
NS: no significance.
Compared with the Control, PC severity was significantly reduced in incision metastases, pulmonary metastases, pleural effusion, retroperitoneal metastases,
kidney capsule invasion, abdominal wall cancer and pelvic seeding in the HIPEC. Compared with the HIPEC, PC severity was significantly reduced in the cancerous
diaphragm, kidney capsule invasion, intestine wall seeding and mesentery seeding in the PDOX, and in the cancerous diaphragm, intestine wall seeding,
mesentery seeding and abdominal wall cancer in the DOX. There were no statistical differences between the PDOX and DOX in systemic metastases.
Figure 5 Pulmonary metastases (panel A) and liver metastases (panel B) in this study. (A1)(B1) showed exact number of lung and liver
metastases in each rabbit of the 4 groups, respectively; (A2 to A5) showed representative lung metastases in the Control, the HIPEC, the PDOX
and the DOX, respectively; (B2 to B5) showed representative liver metastases in the Control, the HIPEC, the PDOX and the DOX, respectively;
(A6) showed micrographs of lung metastases in the HIPEC, characterized by cancer invasion, pulmonary tissue suppression, intravascular tumor
thrombus formation and conspicuous inflammatory cells infiltration (A6-1, HE stain, 200×)(A6-2, HE stain, 400×). (B6) showed micrographs of liver
metastases in the Control, characterized by extensive liver tissue destruction, invading cancer cells, inflammatory cells infiltration, and hemorrhage
in liver tissue (B6-1, HE stain, 100×)(B6-2, HE stain, 200×).
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Table 3 Blood routine tests and biochemical test results in 4 groups of rabbits [range (median)]
Group D2 D6 D14 D36*
n Value p n Value p n Value p n Value p
Red blood cells (T/L)
Control 10 5.03-6.93 (6.26) 0.849 10 5.08-7.76 (6.07) 0.494 10 4.29-6.32 (5.54) 0.382 0 - 0.203
HIPEC 10 5.13-7.58 (6.48) 10 4.66-7.15 (5.65) 10 3.54-7.30 (5.68) 7 4.28-7.36 (5.28)
PDOX 10 4.17-7.16 (5.94) 10 4.97-6.49 (5.61) 10 4.38-5.82 (5.05) 10 4.46-6.03 (5.47)
DOX 10 5.03-6.84 (6.09) 10 5.03-6.70 (5.88) 10 3.65-6.36 (5.08) 9 4.12-6.40 (4.94)
White blood cells (G/L)
Control 10 5.3-9.6 (8.6) 0.785 10 4.5-14.1 (9.9) 0.446 10 6.0-10.3 (7.8) 0.601 0 - 0.013
HIPEC 10 4.4-12.3 (7.4) 10 4.5-12.7 (9.3) 10 3.2-12.1 (10.7) 7 6.9-13.7 (7.5)
PDOX 10 5.9-13.2 (8.2) 10 6.1-12.5 (8.8) 10 4.6-14.4 (9.0) 10 4.9-11.1 (7.7)
DOX 10 3.6-10.5 (7.8) 10 4.7-12.2 (7.3) 10 4.6-12.5 (10.2) 9 3.9-6.4 (5.3)
Platelets (G/L)
Control 10 387-579 (480) 0.494 10 317-836 (555) 0.362 10 451-917 (657) 0.601 0 - 0.009
HIPEC 10 229-634 (373) 10 363-758 (408) 10 390-709 (489) 7 262-598 (451)
PDOX 10 382-592 (456) 10 395-856 (493) 10 328-1002 (500) 10 201-532 (363)
DOX 10 330-647 (476) 10 363-878 (464) 10 390-939 (654) 9 115-319 (244)
Alanine transaminase (U/L)
Control 10 31-52 (38) 0.463 10 34-54 (41) 0.525 10 21-54 (37) 0.245 0 - 0.838
HIPEC 10 24-47 (40) 10 21-62 (35) 10 31-66 (42) 7 30-59 (48)
PDOX 10 28-52 (40) 10 24-59 (37) 10 32-55 (45) 9 25-79 (40)
DOX 10 29-59 (35) 10 30-59 (39) 10 34-61 (48) 8 26-76 (42)
Aspartate transaminase (U/L)
Control 10 19-54 (35) 0.895 10 30-52 (36) 0.525 10 37-58 (43) 0.309 0 - 0.473
HIPEC 10 23-59 (38) 10 11-55 (35) 10 27-78 (34) 7 25-50 (36)
PDOX 10 22-47 (37) 10 17-49 (39) 10 27-69 (36) 9 20-41 (30)
DOX 10 24-47 (37) 10 24-49 (30) 10 23-86 (36) 8 31-60 (39)
Blood urea nitrogen (mmol/L)
Control 10 4.40-5.80 (4.80) 0.206 10 4.51-10.44 (4.81) 0.525 10 3.29-9.82 (6.32) 0.185 0 - 0.473
HIPEC 10 3.70-8.14 (5.10) 10 3.57-11.04 (5.35) 10 4.32-9.29 (7.50) 7 5.25-8.67 (6.38)
PDOX 10 3.58-7.66 (5.82) 10 3.32-11.58 (6.68) 10 6.52-13.58 (7.63) 9 4.71-8.05 (5.35)
DOX 10 1.76-7.90 (5.01) 10 3.32-10.00 (5.59) 10 1.76-10.53 (7.80) 8 4.50-9.26 (6.27)
Creatinine (μmol/L)
Control 10 45.05-64.50 (60.50) 0.736 10 22.10-73.20 (55.00) 0.736 10 41.40-71.40 (50.25) 0.083 0 - 0.838
HIPEC 10 43.30-80.65 (57.35) 10 22.20-81.55 (46.97) 10 31.10-83.37 (52.96) 7 59.87-76.84 (66.51)
PDOX 10 42.80-75.80 (61.87) 10 22.13-86.25 (69.65) 10 45.30-75.80 (66.25) 9 44.38-79.56 (62.47)
DOX 10 22.30-69.30 (55.81) 10 27.28-75.90 (63.45) 10 42.38-73.76 (69.37) 8 47.72-78.64 (59.50)
Creatine kinase (U/L)
Control 10 74.3-205.6 (131.6) 0.864 10 81.3-247.8 (147.9) 0.878 10 71.4-182.1 (138.9) 0.968 0 - 0.473
HIPEC 10 78.8-259.2 (137.8) 10 66.8-248.9 (145.3) 10 63.4-225.2 (141.8) 7 98.3-265.1 (153.0)
PDOX 10 87.9-194.2 (139.4) 10 69.9-256.1 (144.4) 10 70.0-240.8 (130.6) 9 109.2-251.5 (195.2)
DOX 10 98.3-256.1 (152.4) 10 56.4-250.2 (135.8) 10 80.5-261.2 (133.8) 8 101.1-407.6 (228.1)
Creatine kinase mb isoenzyme (U/L)
Control 10 73.0-162.5 (129.8) 0.717 10 62.5-195.6 (127.2) 0.878 10 57.0-199.8 (119.8) 0.509 0 - 0.040
HIPEC 10 74.2-228.2 (137.3) 10 42.9-219.8 (129.7) 10 52.8-237.7 (146.5) 7 50.2-188.1 (126.1)
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Table 3 Blood routine tests and biochemical test results in 4 groups of rabbits [range (median)] (Continued)
PDOX 10 59.2-228.1 (133.9) 10 42.5-197.7 (133.2) 10 74.9-241.5 (158.2) 9 58.9-209.8 (143.7)
DOX 10 94.3-207.7 (122.1) 10 53.9-202.3 (128.2) 10 94.3-238.6 (148.4) 8 106.2-656.5 (259.3)
*Part of the data is not available because of animal death at the set time.
By 2-sided nonparametric test.
White blood cells on D 36, comparison between groups: p = 0.001, DOX vs. HIPEC; p = 1.000, PDOX vs. HIPEC; p = 0.005, PDOX vs. DOX; Platelets on D 36,
comparison between groups: p = 0.041, DOX vs. HIPEC; p = 0.637, PDOX vs. HIPEC; p = 0.070, PDOX vs. DOX; Creatine kinase mb isoenzyme on D 36, comparison
between groups: p = 0.012, DOX vs. HIPEC; p = 0.593, PDOX vs. HIPEC; p = 0.131, PDOX vs. DOX.
Hematological toxicities with marked reduction in white blood cells (p < 0.05) and platelets (p < 0.05), as well as cardiac toxicities with significant increases in
creatine kinase mb isoenzyme (p < 0.05) were observed on d 36 after systemic chemotherapy in the DOX.
Tang et al. Molecular Cancer 2014, 13:44 Page 10 of 17
http://www.molecular-cancer.com/content/13/1/44PDOX to gastric PC. Compared with the Control, the
OS was extended by at least 70% (18 d) in the HIPEC
(p < 0.001). Compared with the HIPEC, the OS was ex-
tended by at least 40% (17 d) with DOX therapy (p = 0.029)
and by 58% (24 d) with PDOX treatment (p = 0.021).
In currently available chemotherapeutic regimens, anthra-
cyclines are important drugs, as is well demonstrated in the
MAGIC trial [26-28]. Anthracyclines cause cell damage by
intercalating into DNA, leading to chromatin unfolding and
aggregation, which ultimately results in apoptosis [29].
However, like many cytotoxic agents, anthracyclines can
cause serious organ damages. With DOX, toxicity to the
heart and bone marrow are usually dose-limiting, with the
maximum tolerated dose (MTD) far below the minimum
curative dose (MCD). Therefore, strategies to shield the
heart and bone marrow by excluding DOX from them have
long been a top priority. Another strategy has been to target
the drug to the tumor by attaching it to some tumor-
binding moiety, e.g. a tumor-specific monoclonal antibody
(MAb) such as trastuzumab used in chemotherapy for
HER2-positive GC [30]. Drawbacks to the use of MAbs
have been that (1) the limited diffusion of MAbs due to
their large macromolecules into solid tumors could com-
promise their potency; (2) heterogeneous antigen expres-
sion in large tumors will evidently lead a portion of tumor
cells in the solid tumor unresponsive to MAbs; (3) the
tumor Ag that binds the MAb is never completely tumor-
specific, so that some of the drug goes where it does harm;
(4) foreign MAbs are often immunogenic; and (5) MAbs
therapy is very expensive [31-33].
In the present study, normal organs are protected by
masking the cytotoxic drug DOX with a simple dipep-
tide that renders it nontoxic. At the tumor the mask is
removed by CTSB, a ubiquitous proteolytic enzyme that
is so destructive to tissue that normally it occurs only
within cells, encased in lysosomes [34]. Only tumor cells
secrete CTSB externally, confined to their plasma mem-
branes, for the purpose of penetrating basement mem-
brane and extracellular barriers as they spread [35]. The
prodrug PDOX is rapidly cleaved by CTSB at the Lys-
PABC bond [16]. The resulting PABC-DOX decomposes
at once to para-aminobenzyl alcohol, CO2 and free DOX
[16,21]. The PABC self-immolating linker is necessary
because the CTSB’s active site cannot accommodate thebulky DOX molecule, but the smaller PABC fits into the
active site [16]. Free DOX released right on the tumor
cells penetrates them readily, killing them. To be sure, a
certain portion of the free drug may drift away from the
tumor, but the concentration ratio tumor/heart-bone
marrow should be much higher than if the DOX is given
as the free drug, when the expected ratio is about 1. In
this way, even without a positive targeting agent like a
MAb it is possible to raise the MTD without signifi-
cantly raising the MCD. The goal is to raise the MTD
above the MCD, where cures become possible, but even
short of that, a rise in the MTD/MCD ratio will enhance
the effect.
In the previous study [16], human plasma stabilities of
PDOX and releasing rates of free DOX were measured.
The results indicated that PDOX was not hydrolyzed
(no observable changes) over 6 - 7 h in human plasma
without CTSB, but hydrolyzed in 16 min in CTSB rich
conditions, and the appearance of DOX correlated pre-
cisely with the disappearance of PDOX at 495 nm, sug-
gesting that PDOX could be stable in blood circulation
and effectively released at the CTSB-rich tumor site.
The evidence implies that PDOX could stay relatively
stable in human blood circulation for a reasonable time,
but the rabbit plasma stability of PDOX was not mea-
sured in this study.
DOX is one of the most efficacious anticancer drugs
with limited usage due to its dose‑dependent toxicities
to the heart, kidney, liver and bone marrow. Over the
past years, a number of drug delivery strategies have
been developed in an attempt to improve efficacy and
reduce the toxicity profile of DOX. The most successful
drug delivery strategy reported to date has been liposo-
mal DOX, which favors accumulation of the drug at
tumor sites because liposomes easily exit the blood-
stream at sites of leaky vasculature but do not readily
exit the circulation in healthy tissues, such as the heart,
with its “tight” endothelial capillary junctions [36]. Such
theoretical advantages have been confirmed by phase III
clinical studies on metastatic breast cancer, which dem-
onstrated that liposomal DOX could achieve similar or
slightly better clinical efficacy but with significantly re-
duced cardiac and hematological toxicities, in compari-
son with conventional DOX [37,38]. Compared with
Figure 6 Light micrographs and electron transmission micrographs of rabbit myocardium. Top panel (HE stain, 400×), routine
histopathological features of rabbit myocardium at longitudinal section (inserts on the upper right corner, sagittal section), where C1, H1 and P1
demonstrated clean and clear normal myocardial fibers in orderly arrays, but D1 showed coagulation necrosis of the myocardium with deep red
stained cytoplasm and the karyopyknosis of the myocardium. Middle upper panel (10,000×), electron transmission micrographs of the myocardium
focusing on the features of nuclei and peri-nuclear mitochondria, where C2, H2 showed abundant mitochondria packed around normal nucleus,
P2 showed rich mitochondria scattered around normal nucleus, but D2 showed nearly absent mitochondria around the morphologically
senile and degenerative nucleus (yellow star showing enlarged nucleus due to swelling and the eccentric aggregation of heterochromatin,
and green arrows showing conspicuous inward contraction of the nuclear membrane ). In addition, partial myocardium-lytic necrosis (yellow
arrow) and mitochondria-pyknosis away from the nucleus (red arrow) were also evident in DOX treated animals. Middle lower panel (20,000×),
electron transmission micrographs of the myocardium specifically focusing on the detailed morphological changes of mitochondria, where C3 and
H3 showed normal mitochondria morphology, P3 showed normal mitochondria morphology but with slightly dilated cristae in some mitochondria,
but D3 showed conspicuous mitochondria-pyknosis with significantly smaller size and highly packed cristae (red arrows) and completely disintegrated
mitochondria reducing to high electron-density bodies (blue arrows). Bottom panel (20,000×), electron transmission micrographs of the myocardium
focusing on the detailed morphological changes of intercalated discs, where C4, H4 and P4 showed complete, clear and continuous lines of normal
intercalated discs (white arrows), but D4 showed obscure, loosing and discontinuous intercalated discs (white arrows).
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ecule designed for different antitumor mechanisms.
Since we did not perform direct comparisons of effica-
cies and side effects between these two agents, it is likely
that PDOX would not have an advantage in cardiac tox-
icity if it were compared to liposomal DOX.
In this study, animals receiving DOX treatment showed
significant hematological toxicities with marked reductionof white blood cells and platelets, as well as cardiac tox-
icities with significant increases in creatine kinase mb
isoenzyme, which is sensitive marker of cardiac toxic-
ities, evident myocardium coagulation necrosis under
histopathological studies. No hepatic and renal toxic-
ities were observed in the DOX. In contrast, these toxic
effects were not evident in animals receiving PDOX
treatment.
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lowing myocardial damages in rabbits: sarcoplasmic
vacuolization, mitochondrial disruption, and myofibrillar
lysis, which became more serious along with the increase
of DOX dose [39], while demonstrated marked mito-
chondrial damage and vacuolization in DOX-treated
mouse hearts [40]. Disruption or loss of myofibrils and
vacuolization of the cytoplasm, mitochondria changes,
patchy necrosis, and inflammatory cells were observed
in DOX-treated rats [41]. Heavily contracted fibrils and
condensed mitochondria were seen in TEM of heart
cells in DOX-treated dogs [42]. In this study, DOX in-
duced mitochondria‑centered cardiac injuries involving
significant nuclear degenerative changes, mitochondria de-
letion in the peri-nucleus region, mitochondria-pyknosis,
and discontinuation of intercalated discs under electron
microscopy. These results were similar to the cardiac tox-
icity profiles in the above literatures. However, such toxic
effects were not evident in the PDOX, even though the
dosage of PDOX was 5.55-fold that of DOX. In addition,
the hematologic, hepatic and renal toxicities were also less
evident in PDOX than in DOX. Therefore, PDOX demon-
strated reduced overall toxicity in comparison with DOX.
In conclusion, this study successfully synthesized PDOX
with high chemical purity and good water solvability.
PDOX is a newly synthesized molecular targeting prodrug
of DOX, with defined chemical-physical properties. Com-
pared with DOX, PDOX has similar efficacy but reduced
hematological and cardiac toxicities in treating rabbit
model of gastric PC.Methods
Synthesis and identification of PDOX
All reactions were carried out in dried flasks under an
atmosphere of dry nitrogen unless otherwise specified.
The reactions monitored either on HPLC or TLC for
completion. All reagents and solvents used were used
as received without further purification unless other-
wise stated. Chemical purity of the intermediates and
final compound was determined on Agilent 1100 series
instrument. LC-MS was performed on Agilent 1100
instrument with Zorbax column (4.6 × 150 mm) eluted
with 0.1% trifluoroacetic acid water/0.1% trifluoroacetic
acid acetonitrile at 1 mL/min flow rate. Column chro-
matography was performed on silica gel 60 (40-63 μm).
Nuclear magnetic resonance (NMR) spectra were recorded
on a Varian 300 instrument operating at 300 MHz (1H)
or Bruker AC 500 instrument operating at 500 MHz
(1H), 125 MHz (13C). Chemical shifts δ were reported
in parts per million (ppm) from tetramethylsilane
(TMS) as internal standards (0.00 ppm). Abbreviations
for signal coupling are as follows: s = singlet, d = doublet,
t = triplet, q = quartet, dd = double doublet, m =multiplet.High resolution mass spectrum (ES, positive) was deter-
mined on a Thermo LTQ FT Ultra Mass Spectrometer.
PDOX was synthesized according to the previously
reported chemical process [16-18], with the following
7 major steps.
Step-1: Fmoc-Lys(MMT) 1
In a 2 L r.b. flask, Fmoc-L-Lysine hydrochloride (47.6 g,
112.8 mmol) was suspended in anhydrous dichlorometh-
ane (500 mL). Under nitrogen, at room temperature the
trimethylchlorosilane (30 mL, 2.1 eq) was added, followed
by diisopropylethylamine (20.6 mL, 1.05 eq). The reaction
mixture was then heated to reflux for 1 h, and the clear
solution formed during this time. The reaction mixture
was then cooled to 0°C, and the diisopropylethylamine
(62 mL, 3.1 eq) was added in, followed by p-anisyl-
diphenylmethyl chloride (36.6 g, 1.05 eq). The reaction
mixture was stirred at room temperature for 16 h. The
solvent was evaporated and the residue was re-dissolved
in ethyl acetate (600 mL). The solution was washed
twice by pH 5 buffer solution (biphosphate, 300 mL × 2),
and dried over sodium sulfate. After filtration and evapor-
ation, a foam solid obtained (69.4 g 96%). H1-NMR
(CDCl3, ppm) 1.26 (m, 2H), 1.68 (m, 4H), 2.45 (m, 2H),
3.71 (s, 3H), 4.05-4.40 (m, 4H), 6.81 (d, 2H), 7.15-7.77
(m, 20H).
Step-2: Lys(MMT) 2
In a 1 L flask, under nitrogen, Fmoc-Lys(MMT) 1
(26.3 g, 41 mmol) was dissolved in a mixture of 1:1 di-
chloromethane acetonitrile (400 mL). The diethylamine
(400 mL) was added at room temperature and the result
solution was stirred for 1.5 h. The solvent was evapo-
rated to dryness, and the residue was treated with aceto-
nitrile (200 mL) and the ether 400 mL. the solid was
collected by filtration. The solid crude product was
stirred with a mixture solvent of dichloromethane
methanol (100 mL: 20 mL). The solid side product was
filtrated off. After evaporation the solid product was
dried by high vacuum for 10 h and obtained 16 g (94%).
H1-NMR (DMSO-d6, ppm) 1.34-1.72 (m, 6H), 2.05
(m, 2H), 3.38 (m, 1H), 3.68 (s, 3H), 3.71 (d, 2H), 7.03-
7.40 (m, 12H).
Step-3: Ac-Phe-Lys(MMT) 3
In a 1 L flask under nitrogen, the Lys(MMT) 2 (20.5 g,
48.9 mmol) was dissolved in dimethoxyethane (350 mL),
and the solution of lithium hydroxide (2.05 g, 1 eq) in
water (125 mL) was added in. A solution of Ac-Phe-OSu
(13.9 g, 1 eq) in dimetoxyethane (350 mL) was added
during 15 min, and the reaction mixture was stirred at
room temperature for 16 h. The solvent was evaporated
as much as possible, and the residue was taken by ethyl
acetate (350 mL). This solution was washed by pH 4
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dried over sodium sulfate. After evaporation, the pale-
yellow solid was dried by high vacuum for at least 5 h,
and obtained 26.5 g (90%). H1-NMR (CDCl3/CD3OD),
ppm) 1.22 (m, 2H), 1.58 (m, 3H), 1.71 (m, 1H), 1.82
(s, 3H), 2.49 (m, 2H), 3.00 (m, 2H), 3.75 (s, 3H), 4.26
(t, 1H), 4.63 (t, 1H), 6.82 (d, 2H), 7.10-7.43 (m, 17H).
Step-4: Ac-Phe-Lys(MMT)-PABOH 4
In a 1 L flask under nitrogen, Ac-Phe-Lys(MMT) 3
(26.5 g, 43.65 mmol) and di-t-butyl-pyrocarbonate (14.3 g,
1.5 eq) were dissolved in dichloromethane (600 mL), and
at room temperature, the pyridine (3.7 mL, 1.05 eq) was
added in. The resulting mixture was stirred for 15 min,
and then, p-aminobenzyl alcohol (8 g, 1.5 eq) was added
in. The reaction was stirred for 16 h, and the solvent was
evaporated to dryness. The residue was treated with ether
(200 mL), and the solid product was collected by filtration,
and washed by fresh ether (50 mL × 2). After drying by
high vacuum for 10 h, the off white solid obtained 26.2 g
(84%). H1-NMR (CDCl3/CD3OD), ppm) 1.31 (m, 1H),
1.50 (m, 1H), 1.71-2.01 (m, 7H), 2.18 (m, 2H), 3.00
(m, 2H), 3.74 (s, 3H), 4.40 (t, 1H), 4.61 (s, 2H), 4.68
(m, 1H), 6.67 (d, 1H), 6.77 (d, 1H), 7.00-7.55 (m, 21H),
8.92 (br, 1H).
Step-5: Ac-Phe-Lys(MMT)-PABC-PNP 5
In a 1 L flask under nitrogen, Ac-Phe-Lys(MMT)-PABOH
4 (25.5 g, 35.7 mmol) and bis-p-nitrophenylcarbnate
(32.5 g, 3 eq) was dissolved in anhydrous dichloromethane
(600 mL). The fresh powdered molecular sieve 4 (50 g)
was added followed by addition of diisopropylethylamine
(18.5 mL, 3 eq). The reaction mixture was stirred at room
temperature for 20 h, and filtrated through a pad of celite.
After evaporation of the solvent, the crude compound was
loaded to a silica gel column, and the desired product was
eluted with hexane-ethyl acetate (50% to 100%). The pure
product was obtained after evaporation of solvents, gives
10.5 g (34%). H1-NMR (DMF-d7, ppm) 1.43 (m, 2H), 1.58
(m, 2H), 1.72 (m, 1H), 1.87 (m, 4H), 2.09 (m, 2H), 2.4
(br, 1H), 3.05 (m, 1H), 3,78 (s, 3H), 4.52 (m, 1H), 4.72
(m, 1H), 5.36 (s, 2H), 6.90 (d, 2H), 6.77 (d, 1H), 7.29
(m, 16H), 7.41 (d, 2H), 7.50 (d, 4H), 7.68 (d, 2H), 7.81
(d, 2H), 8.13 (s, 1H), 8.19 (d, 1H), 8.41 (d, 2H), 10.11 (s, 1H).
Step-6: Ac-Phe-Lys(MMT)-PABC-DOX 6
In a 1 L flask under nitrogen, Ac-Phe-Lys(MMT)-PABC-
PNP 5 (11 g, 12.5 mmol) and DOX hydrochloride (7.6 g,
1.05 eq) were dissolved in dimethylformamide (600 mL).
The diisopropylethylamine (2.3 mL, 1.05 eq) was added,
and the reaction mixture was stirred at room temperature
for 48 h. The reaction mixture was diluted with ethyl acet-
ate (4 L), and washed with water (1 L × 4), and dried over
sodium sulfate. After evaporation, the crude product waspurified by silica gel column and eluted dichloromethane-
methanol (5% to 15%). After evaporation and drying,
the pure product obtained 9.8 g (61%). H1-NMR (DMF-
d7, ppm) 1.25 (d, 3H), 1.41 (m, 2H), 1.72 (m, 2H), 1.87
(m, 4H), 2.09 (m, 4H), 2.34 (m, 4H), 3.12 (m, 4H), 3.63
(br, 1H), 3,78 (s, 3H), 3.92 (m, 1H), 4,11 (s, 3H), 4.33
(m, 1H), 4.51 (m, 1H), 4.68 (m, 1H), 4.81 (s, 2H), 4.90
(m, 1H), 5.00 (br, 2H), 5.13 (br, 1H), 5.40 (br, 1H), 5.61
(s, 1H), 6.78 (d, 1H), 6.89 (d, 2H), 7.29 (m, 17H), 7.41
(d, 2H), 7.50 (d, 4H), 7.70 (m, 3H), 8.05 (m, 3H), 9.98
(s, 1H).Step-7: Ac-Phe-Lys-PABC-DOX-HCl 7
In 1 L flask under nitrogen, Ac-Phe-Lys(MMT)-PABC-
DOX 6 (9.8 g, 7.6 mmol) was suspended in a mixture of
anisole (83 mL, 100 eq) and dichloromethane (260 mL),
then dichloroacetic acid (6.2 mL, 10 eq) was added. The re-
action mixture was stirred at room temperature for 1.5 h,
and the ethyl acetate (2 L) was added, and keep stirring for
2 h. The solid product was collected by filtration, and the
solid was re-dissolved in methanol (400 mL). The solution
was loaded to a AG2-X8 ion resin (Cl form, 250 g) ex-
change column, and eluting with methanol. The colorful
fraction, which content product, was collected and evapo-
rated to dry. The solid was treated with dichloromethane
(10 mL) and after filtration, the product was dried by high
vacuum for constant weight produced 7.1 g (95%).H1-NMR (DMSO-d6, ppm
1.12 (d, 3H), 1.47 (m, 4H), 1.75(m, 4H), 1.83 (m, 1H), 2.11
(d, 1H), 2.2 (d, 1H), 2.67-3.02 (m, 4H), 3.74 (m, 1H), 3.86
(s, 3H), 4.13 (m, 2H), 4.38, (m, 1H), 4.51 (m, 1H), 4.50
(br, 2H), 4.75 (d, 1H), 4.89 (br, 2H), 5.21 (br, 1H), 5.48
(s, 1H), 6.89 (d, 1H), 7.11-7.26 (m, 4H), 7.59 (d, 1H),
7.64 (dd, 1H), 7.85-7.90 (m, 3H), 8.16, (d, 1H), 8.32 (d, 1H),
10.11 (s, 1H), 13.16 (s, 1H).C13-NMR (DMSO-d6, ppm)
δ 186.6, 186.5, 171.8, 170.8, 170.1, 169.8, 161.1, 156.4,
155.7, 154.9, 138.9, 138.7, 138.3, 137.8, 136.5, 135.7,
134.8, 134.4, 132.3, 129.6, 128.8, 126.7, 126.6, 120.2,
119.5, 119.6, 110.9, 110.8, 100.7, 75.3, 70.1, 68.4, 76.1,
65.3, 64.1, 56.8, 55.1, 54.5, 53.7, 48.9, 47.5, 39.2, 38.8,
36.8, 32.4, 31.6, 30.2, 26.9, 22.8, 22.4, 17.4.Agents and cells
Apart from PDOX described above, other agents were ob-
tained from commercial sources, including DOX hydro-
chloride for Injection (Pharmacia, Milan, Italy), Docetaxel
(Wanle Pharmaceuticals Co., Ltd. Shenzhen, China) and
Carboplatin (Qilu Pharmaceuticals Co., Ltd. Shandong,
China).
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The animal study protocol was approved by the Animal
Welfare Committee of Wuhan University, complied with
the Helsinki Declaration. The animal study was com-
pleted in the Animal Biosafety Level 3 Laboratory at
the Animal Experimental Center of Wuhan University
(Animal Study Certificate ID: No.00022310).
Animals
Forty male New Zealand white rabbits, body weight be-
tween 2.5-3.0 kg, were obtained from Animal Biosafety
Level 3 Laboratory at the Animal Experimental Center
of Wuhan University (Approval ID: SCXK 2008-0004).
The animals were individually housed and allowed free
access to standard laboratory food and water as well as
12 h of light and dark cycle per day.
Tumor strain and tumor cell preparation
Rabbit VX2 carcinoma was used to establish GC with
PC in this study. The VX2 tumor is a transplantable
rabbit squamous cell carcinoma, characterized by rapid
tumor growth and early metastasis, established from a
virus-induced papilloma by Rous and coworkers [43].
The tumor was maintained by successive in vivo trans-
plantation into the hind leg of a carrier rabbit used for
every passage.
When the VX2 tumor grew to about 2 cm in diameter
on the carrier rabbit, the animal was anesthetized by ear
vein injection of 2% pentobarbital sodium (30 mg/kg).
After skin preparation and disinfection, the tumor was ex-
cised from the carrier rabbit and placed in icy cold 0.9%
sodium chloride solution. Tumor tissue was minced into
approximately 1.0-2.0 mm3 fragments and suspended in
2 mL of normal saline, then drawn into a 2 mL injector.
Other tumor tissues about 3.0-5.0 mm3 were placed into
the homogenizer embedded in ice bath, to which 3 mL of
icy cold normal saline was added, and the tumor cells sus-
pension was made, with the tumor cells concentration ad-
justed to 5 × 1010 vial cells/L.
Construction of rabbit model of gastric PC
Rabbit VX2 carcinoma was used to establish gastric PC
in this study. All rabbits had overnight fasting before ex-
periment, but water was given ad libitum. The animals
were anesthetized by ear vein injection of 2% pentobar-
bital sodium (30 mg/kg). The abdominal skin was
cleaned and disinfected. Tumor cells were injected into
the stomach submucosa layer to construct rabbit model
of gastric PC as described previously [24,25]. Briefly, a
midline incision of 3 cm long was made beginning
2 cm below the xyphoid and the upper abdomen was
open. The stomach was exposed, 0.1 mL of tumor cells
(5 × 1010 vial cells/L) was injected into the submucosal
layer of the stomach, through the serosal layer and themuscle layer, the injection site was pressed for 1 min to
keep the injected tumor cells in place, and the abdomen
was closed with a double layer 3-0 vicryl interrupted
suture. After tumor inoculation, Penicillin G at the dose
of 100,000 IU/d was intramuscularly injected to each
animal for 3 d.
Randomization and treatment
When animal model construction has been confirmed
successful on d 8 after operation, these rabbits were ran-
domly divided into 4 groups according to a computer
generated randomize number, 10 animals in each group:
the Control (n = 10) was observed for natural course of
disease progression without any intervention; the HIPEC
(n = 10) receiving CRS plus HIPEC (docetaxel 10.0 mg
and carboplatin 50.0 mg in 250 mL normal saline, at
42.5 ± 0.5°C for 30 min); the PDOX (n = 10) and the
DOX (n = 10) receiving systemic chemotherapy with
PDOX 50.0 mg/kg (10.0 mg/kg every 4 d for 5 cycles) or
DOX 5.0 mg/kg (1.0 mg/kg every 4 d for 5 cycles) after
CRS +HIPEC, respectively; The CRS + HIPEC was per-
formed on d 8 while the systemic chemotherapy was ini-
tiated on d 16 after model construction.
CRS plus HIPEC
For the three treatment groups, CRS +HIPEC was per-
formed on 8 d after tumor cells inoculation. Rabbits
were given 2% pentobarbital sodium (30 mg/kg) intra-
venously (i.v) for anesthesia. The abdominal skin was
cleaned and disinfected. The abdominal exploration was
performed through a midline incision of 8 cm long be-
ginning 1 cm below the xyphoid. Once the abdomen
was open, detailed evaluation of the PC was conducted
in different regions including the parietal peritoneum,
visceral peritoneum, the omentum, stomach, liver,
spleen, intestinal wall, bladder and other pelvic organs.
An ePCI score system [44] was developed to record the
experimental peritoneal carcinomatosis index of the ani-
mals in each group, which took into consideration of
tumor nodule sizes, distributions and the characteristics
of ascites. In this system, the abdominal cavity of rabbit
was divided into 4 regions: region I, sub-diaphragm; re-
gion II, the liver, spleen, stomach and affiliated liga-
ments; region III, small intestine, colon, mesenterium
and abdominal wall; and region IV, pelvic cavity urogeni-
tal system and rectum. The detailed scoring criteria were
modified from similar reporting systems on rat and mice
PC models and set as the following: score 0, no tumor
nodules throughtout the region; score 1, nodule size less
than 5 mm in greastest diameter; score 2, nodule size
greater than 5 mm and up to 20 mm; score 3, nodule
size greater than 20 mm. If bloody ascites occurred, it
was set as score 1. The sum of all the scores was the
ePCI of the animal (ranging from 0 to 13). Thereafter,
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tectomy, and optimal removal of tumor nodules. Unre-
sectable tumors were cauterized. The gastric tumor
itself, however, was not removed but treated by injection
of absolute alcohol. HIPEC was performed just before
the closure of abdominal cavity after completion of CRS,
as this open technique was believed to provide optimal
thermal homogeneity and spatial diffusion [25], with
250 mL of heated saline containing 10 mg of docetaxel
and 40 mg of carboplatin for each animal. The abdom-
inal cavity was rinsed twice with 250 mL of normal sa-
line preheated to 42.5°C and perfusion tube was placed
in pelvic cavity just before HIPEC. The perfusion equip-
ment consisted of a miniature heat exchanger and a
roller pump, allowing perfusion with a variable dynamic
flow of 6-12 mL/min. An inflow catheter was inserted
into the upper abdomen between the hepatic and dia-
phragmatic surface and an outflow catheter was placed
at the pelvic floor. The perfusion solution was heated to
42.5 ± 0.5°C and infused into the peritoneal cavity at a
rate of 10 mL/min through the inflow tube introduced
from the automatic perfusion pump. The perfusion in
the peritoneal cavity was stirred manually to make equal
spatial distribution.
The temperature of the perfusion solution in periton-
eal space was kept at 42.5 ± 0.5°C and monitored using a
thermometer on real time. The total HIPEC time was
30 min, after which the perfusion solution in the abdom-
inal cavity was removed. Twenty min before surgery,
100 mL of 0.9% sodium chloride solution with 1 g of cef-
triaxone powder, 2 mL of 10% potassium chloride solu-
tion and 20 mL of 50% glucose solution was infused
intravenously for rehydration, nutrition support and in-
fection control in all the four groups of animals. Such
treatment was continued for 3 d.
Chemotherapy with PDOX and DOX after CRS + HIPEC
After CRS +HIPEC, the PDOX (n = 10) received systemic
chemotherapy with PDOX 50.0 mg/kg (10.0 mg/kg and
3.0 mL/kg every 4 d for 5 cycles) on d 16, d 20, d 24, d 28,
and d 32 after tumor cells inoculation respectively; the
DOX (n = 10) received systemic chemotherapy with DOX
5.0 mg/kg (1.0 mg/kg and 3.0 mL/kg every 4 d for 5 cycles)
at the same time; the Control and the HIPEC received
3.0 mL/kg 5% dextrose instead of chemotherapy drugs at
the same time. All drugs were slowly injected i.v through
the ear vein of rabbits. For each animal, 2.5 mg of dexa-
methasone was injected i.v 20 min before chemotherapy,
and an additional 2 mL of 5% dextrose was injected i.v after
PDOX or DOX injection to reduce local vascular damage.
Animal observation and disease course monitoring
The general status of the animals was daily recorded in a
standard form. For pathological studies, euthanasia wasperformed on the rabbits by overdose injection of 2%
pentobarbital sodium through the ear vein. Post mortem
pathological examinations included gross pathology such
as tumor size and distributions; local tumor features of
GC such as ulcer formation, intestinal obstruction and
perforation; special features of PC such as bloody ascites,
discrete or confluent tumor nodules on the peritoneum
and omentum cake; metastases to major organs such as
the livers and the lungs.Blood routine tests and biochemical test results
For laboratory studies, 3 mL of blood was harvested from
ear vein on 2 d before tumor cells inoculation as the base-
line (D-2), 2 d before CRS +HIPEC (D6), 2 d before chemo-
therapy (D14), and 4 d after completion of chemotherapy
(D36). The samples were used for routine peripheral blood
test, liver and kidney functions tests and detection of creat-
ine kinase and creatine kinase mb isoenzyme.Histopathological studies under both optical microscope
and electronic microscope
During the procedure of CRS, the resected omentum,
tumor nodules, enlarged mesenteric lymph nodes were
harvested for HE staining and observation under optical
microscope. After post mortem pathological examina-
tions, myocardial tissues of all the rabbits were harvested
at the first time for the electronic microscope, and all
the suspected organ metastasis tissues were sampled for
routine histopathology study with sections stained by
hematoxylin and eosin (HE stain).Statistical analyses
All data were integrated into a central database. The nu-
merical data were directly recorded, and the category
data were recorded into different categories. The pri-
mary endpoint was OS, and secondary endpoint was
toxicity profile. Survival was analyzed on Kaplan-Meier
survival plots and statistical significance was analyzed
with SPSS software version 15.0 (SPSS Inc., IL, USA),
using the log-rank test. The differences in blood routine
and biochemistry among different groups were tested
using nonparametric test at each time point. Categorized
variables were compared by chi square test (χ2) or Fisher’s
exact test. Two-sided p < 0.05 was considered to be statis-
tically significant.Abbreviations
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